-
公开(公告)号：US20140154239A1
公开(公告)日：2014-06-05
申请号：US13705289
申请日：2012-12-05
IPC分类号： C07K16/24
CPC分类号： C07K16/249 , C07K2317/24 , C07K2317/33 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.
摘要翻译： 本发明包括组合物和方法，其包括选择性中和至少两种干扰素α（“IFNα”）蛋白亚型对于蛋白质亚型A，2，B2，C，F，G，H2，I，J1的生物活性的抗体， K，4a，4b和WA，但不中和IFNα蛋白亚型D的至少一种生物活性。用于测量的生物活性的实例包括MxA启动子的活化或抗病毒活性及其变体，衍生物和片段。 本发明还包括产生抗体的宿主细胞，杂交瘤和浆细胞瘤。 由于其独特的选择性和亲和性，本发明的抗体可用于检测样品或组织和/或治疗应用中的IFNα亚型，包括但不限于IFNα相关病症的治疗和/或改善，例如 如SLE，狼疮，I型糖尿病，牛皮癣，艾滋病和移植物抗宿主病。
-
公开(公告)号：US08333965B2
公开(公告)日：2012-12-18
申请号：US13252335
申请日：2011-10-04
IPC分类号： A61K39/395 , A61K38/00 , C07K16/00 , C12P21/08
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/24 , C07K2317/76
摘要： The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.
摘要翻译： 本发明包括组合物和方法，其包括选择性中和至少两种干扰素α（IFNα）蛋白亚型对于蛋白质亚型A，2，B2，C，F，G，H2，I，J1，K的生物活性的抗体， 4a，4b和WA，但不中和IFNα蛋白亚型D的至少一种生物活性。用于测量的生物活性的实例包括MxA启动子的活化或抗病毒活性及其变体，衍生物和片段。 本发明还包括产生抗体的宿主细胞，杂交瘤和浆细胞瘤。 由于其独特的选择性和亲和性，本发明的抗体可用于检测样品或组织和/或治疗应用中的IFNα亚型，包括但不限于IFNα相关病症的治疗和/或改善，例如 如SLE，狼疮，I型糖尿病，牛皮癣，艾滋病和移植物抗宿主病。
-
公开(公告)号：US20090214565A1
公开(公告)日：2009-08-27
申请号：US12367030
申请日：2009-02-06
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.
摘要翻译： 本发明包括组合物和方法，其包括选择性中和至少两种干扰素α（“IFNα”）蛋白亚型对于蛋白质亚型A，2，B2，C，F，G，H 2，I，J 1的生物活性的抗体， K，4a，4b和WA，但不中和IFNα蛋白亚型D的至少一种生物活性。用于测量的生物活性的实例包括MxA启动子的活化或抗病毒活性及其变体，衍生物和片段。 本发明还包括产生抗体的宿主细胞，杂交瘤和浆细胞瘤。 由于其独特的选择性和亲和力，本发明的抗体可用于检测样品或组织和/或治疗应用中的IFNα亚型，包括但不限于IFNα相关病症的治疗和/或改善，例如 如SLE，狼疮，I型糖尿病，牛皮癣，艾滋病和移植物抗宿主病。
-
公开(公告)号：US20080160030A1
公开(公告)日：2008-07-03
申请号：US11883961
申请日：2006-02-09
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/24 , C07K2317/76
摘要： The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, 1, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.
摘要翻译： 本发明包括组合物和方法，其包括选择性中和至少两种干扰素α（“IFNα”）蛋白亚型对于蛋白质亚型A，2，B2，C，F，G，H2，1，J1的蛋白质亚型的生物活性的抗体， K，4a，4b和WA，但不中和IFNα蛋白亚型D的至少一种生物活性。用于测量的生物活性的实例包括MxA启动子的活化或抗病毒活性及其变体，衍生物和片段。 本发明还包括产生抗体的宿主细胞，杂交瘤和浆细胞瘤。 由于其独特的选择性和亲和力，本发明的抗体可用于检测样品或组织和/或治疗应用中的IFNα亚型，包括但不限于IFNα相关病症的治疗和/或改善，例如 如SLE，狼疮，I型糖尿病，牛皮癣，艾滋病和移植物抗宿主病。
-
公开(公告)号：US08080638B2
公开(公告)日：2011-12-20
申请号：US11883961
申请日：2006-02-09
IPC分类号： C07K16/00 , A61K39/395
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/24 , C07K2317/76
摘要： The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, 1, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the M×A promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.
摘要翻译： 本发明包括组合物和方法，其包括选择性中和至少两种干扰素α（“IFNα”）蛋白亚型对于蛋白质亚型A，2，B2，C，F，G，H2，1，J1的生物活性的抗体， K，4a，4b和WA，但不中和IFNα蛋白亚型D的至少一种生物活性。用于测量的生物活性的实例包括M×A启动子的活化或抗病毒活性及其变体，衍生物和片段。 本发明还包括产生抗体的宿主细胞，杂交瘤和浆细胞瘤。 由于其独特的选择性和亲和性，本发明的抗体可用于检测样品或组织和/或治疗应用中的IFNα亚型，包括但不限于IFNα相关病症的治疗和/或改善，例如 如SLE，狼疮，I型糖尿病，牛皮癣，艾滋病和移植物抗宿主病。
-
公开(公告)号：US07888481B2
公开(公告)日：2011-02-15
申请号：US12367030
申请日：2009-02-06
IPC分类号： C07K16/00 , A61K39/395
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present invention includes compositions and methods that include antibodies that selectively neutralize a bioactivity of at least two interferon alpha (“IFNα”) protein subtypes for the protein subtypes A, 2, B2, C, F, G, H2, I, J1, K, 4a, 4b and WA, but does not neutralize at least one bioactivity of IFNα protein subtype D. Examples of bioactivity for measurement include activation of the MxA promoter or antiviral activity and variants, derivatives and fragments thereof. The invention also includes host cells, hybridomas and plasmacytomas that produce antibodies. Because of their unique selectivity and affinity, the antibodies of the present invention are useful to detect IFNα subtypes in sample or tissue and/or for therapeutic applications that include, but are not limited to the treatment and/or amelioration of an IFNα related disorder such as SLE, lupus, type I diabetes, psoriasis, AIDS and Graft versus Host Disease.
摘要翻译： 本发明包括组合物和方法，其包括选择性中和至少两种干扰素α（“IFNα”）蛋白亚型对于蛋白质亚型A，2，B2，C，F，G，H2，I，J1的生物活性的抗体， K，4a，4b和WA，但不中和IFNα蛋白亚型D的至少一种生物活性。用于测量的生物活性的实例包括MxA启动子的活化或抗病毒活性及其变体，衍生物和片段。 本发明还包括产生抗体的宿主细胞，杂交瘤和浆细胞瘤。 由于其独特的选择性和亲和性，本发明的抗体可用于检测样品或组织和/或治疗应用中的IFNα亚型，包括但不限于IFNα相关病症的治疗和/或改善，例如 如SLE，狼疮，I型糖尿病，牛皮癣，艾滋病和移植物抗宿主病。
-
公开(公告)号：US20050192241A1
公开(公告)日：2005-09-01
申请号：US11067335
申请日：2005-02-25
CPC分类号： A61K38/2006 , A61K38/1709 , C07K14/545 , C07K16/245 , G01N33/6869 , Y10S514/825
摘要： The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.
摘要翻译： 本发明包括用于治疗患有自身炎症的患者的关节炎关节的组合物和方法，例如全身性发作的幼年特发性关节炎，通过在炎症部位施用治疗有效量的至少一种降低或阻断白介素 - 1beta。
-
8.发明申请公开(公告)号：US20120258120A1
公开(公告)日：2012-10-11
申请号：US13527233
申请日：2012-06-19
IPC分类号： A61K31/7088 , A61K38/02 , A61P19/02 , A61K31/355 , A61K31/557 , A61K38/16 , A61K39/395
CPC分类号： A61K38/2006 , A61K38/1709 , C07K14/545 , C07K16/245 , G01N33/6869 , Y10S514/825
摘要： The present invention includes compositions and methods for treating arthritic joints found in patients with auto-inflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks IL-1β receptors.
摘要翻译： 本发明包括用于治疗患有自身炎症的患者的关节炎关节的组合物和方法，例如全身性发作的幼年特发性关节炎，通过在炎症部位施用治疗有效量的至少一种减少或阻断IL-1和bgr的药物 ; 受体。
-
公开(公告)号：US20120148498A1
公开(公告)日：2012-06-14
申请号：US13407362
申请日：2012-02-28
IPC分类号： A61K31/7088 , C07H21/02 , C07K14/00 , C07K16/24 , A61K49/00 , C07D311/72 , A61K39/395 , A61K31/355 , A61K38/02 , A61K31/713 , C07K2/00
CPC分类号： A61K38/2006 , A61K38/1709 , C07K14/545 , C07K16/245 , G01N33/6869 , Y10S514/825
摘要： The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.
摘要翻译： 本发明包括用于治疗患有自身炎症的患者的关节炎关节的组合物和方法，例如全身性发作的幼年特发性关节炎，通过在炎症部位施用治疗有效量的至少一种降低或阻断白介素 - 1＆bgr
-
公开(公告)号：US20100069466A1
公开(公告)日：2010-03-18
申请号：US12568933
申请日：2009-09-29
CPC分类号： A61K38/2006 , A61K38/1709 , C07K14/545 , C07K16/245 , G01N33/6869 , Y10S514/825
摘要： The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.
摘要翻译： 本发明包括用于治疗患有自身炎症的患者的关节炎关节的组合物和方法，例如全身性发作的幼年特发性关节炎，通过在炎症部位施用治疗有效量的至少一种降低或阻断白介素 - 1＆bgr
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.029 秒)
